Ping Mu

Ping Mu is an Associate Professor with tenure in the Department of Urology at Yale School of Medicine and a member of the Yale Cancer Center. His research focuses on understanding molecular mechanisms of drug resistance in prostate and other cancers, employing advanced techniques like organoids, single-cell sequencing, and spatial transcriptomics. His lab pioneers therapeutic strategies to combat resistance, with breakthroughs published in Science, Cancer Cell, and Nature Cancer.

• Education: PhD from Weill Cornell Medical College (2013), Postdoc at Memorial Sloan Kettering Cancer Center (2018).
• Awards: NIH R01/R37 MERIT Awards, DoD grants, AACR NextGen Star Award, Welch Foundation Award.
• Research Interests: Lineage plasticity, epigenetic rewiring, tumor microenvironment, drug resistance mechanisms.

Recent work includes identifying ZNF397 deficiency's role in therapy resistance and developing novel combination therapies. His lab also explores JAK-STAT signaling's role in cancer stemness and APOBEC-driven mutagenesis in prostate tumors.

• Grants: Over $15M in NIH, DoD, and CPRIT funding.
• Labs/Teams: Mu Lab (Yale Cancer Center), part of the Cancer Signaling Networks program.